Splenic marginal zone lymphoma: management specifics. Clinical observation
https://doi.org/10.17650/2782-3202-2024-4-3-93-98
Abstract
Despite having common histological and immunophenotypic characteristics with other marginal zone lymphomas, splenic marginal zone lymphoma (SMZL) has distinctive clinical and biological features. The main indications for therapy of this disease (of primarily indolent progression) are progressive splenomegaly and/or progressive cytopenia. Current clinical management guidelines do not conclusively point to advantages of one certain therapy, and there is no universal algorithm of management of patients with newly diagnosed SMZL manifesting through progressive splenomegaly. Therefore, determination of indications for surgical treatment is an important problem. A clinical observation of a female patient with newly diagnosed advanced SMZL is presented. Due to progressive splenomegaly and hypersplenism symptoms, the patient underwent splenectomy. Personalized multidisciplinary approach allowed to relieve hypersplenism symptoms as quickly as possible, and the absence of postoperative complications with indolent disease progression significantly increased the patient’s quality of life and allowed to continue dynamic observation.
Supporting agencies: The work was performed without external funding
About the Authors
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Department of Oncology
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino; 119991; Bld. 2, 8 Trubetskaya St.; Moscow
M. M. Davydov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Department of Oncology
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino; 119991; Bld. 2, 8 Trubetskaya St.; Moscow
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Yulia Evgenyevna Ryabukhina
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
M. S. Shogenov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
A. G. Zhukov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
E. R. Nigmatullina
MGIMO-MED Medical University
Russian Federation
Russian Federation
143007; 3 Novosportivnaya St.; Moscow region; Odintsovo
References
1. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. WHO classification of tumours series. 5<sup>th</sup> edn. Vol. 11. France, Lyon: IARC, 2022. Available at: https://tumourclassification.iarc.who.int/chapters/63
2. Alaggio R., Amador C., Anagnostopoulos I. et al. The 5<sup>th</sup> edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36(7):1720–48. DOI: 10.1038/s41375-022-01620-2
3. Zucca E., Arcaini L., Buske C. et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(1):17–29. DOI: 10.1016/j.annonc.2019.10.010
4. Santos T.S.D., Tavares R.S., Farias D.L.C. Splenic marginal zone lymphoma : a literature review of diagnostic and therapeutic challenges. Rev Bras Hematol Hemoter. 2017;39(2):146–54. DOI: 10.1016/j.bjhh.2016.09.014
5. Lymphoma of the marginal zone. Clinical recommendations. 2023. (In Russ.).
6. Thieblemont C., Davi F., Noguera M.E. et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park) 2012;26(2):194–202.
7. Olszewski A.J. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol 2012;87(11):E119–22. DOI: 10.1002/ajh.23314
8. Olszewski A.J., Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol 2014;93(3):449–58. DOI: 10.1007/s00277-013-1900-4
9. Kalpadakis C., Pangalis G.A., Angelopoulou M.K., Vassilakopoulos T.P. Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol 2017;30(1–2):139–48. DOI: 10.1016/j.beha.2016.07.004
10. Bonfiglio F., Bruscaggin A., Guidetti F. et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 2022;139(5):732–47. DOI: 10.1182/blood.2021012386
11. Fallah J., Olszewski A.J. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. Hematology 2019;24(1):378–86.
Review
For citations:
Zeynalova P.A., Davydov M.M., Ryabukhina Yu.E., Shogenov M.S., Zhukov A.G., Nigmatullina E.R. Splenic marginal zone lymphoma: management specifics. Clinical observation. MD-Onco. 2024;4(3):93-98. (In Russ.) https://doi.org/10.17650/2782-3202-2024-4-3-93-98
Views:
130
Email this article 